Powered by 
Google Übersetzer
Google Übersetzer
[A blue text on a black background
AI-generated content may be incorrect.]
4basebio PLC
("4basebio" or the "Company")
Director Dealing
CAMBRIDGE, UK - 22 May 2026-4basebio PLC (AIM: 4BB), a company pioneering an
enzymatically-produced DNA technology serving the next generation genetic
medicines markets, announces that on 21 May 2026 it was informed that Dr. Amy
Walker, Chief Executive Officer of the Company, purchased 1,863 ordinary shares
in the capital of the Company through the market.
Further details are set out in the Notification of Dealing Form below.
+--------+---------------+--------+------------+-------------------------------+
|Director|Number of |Purchase|Shareholding|Shareholding following purchase|
|/ PCA |ordinary shares|price |following |as a % of the issued share |
| |urchased |(pence) |purchase |capital |
+--------+---------------+--------+------------+-------------------------------+
|Dr. Amy |1,863 |509.00 |48,529 |0.31% |
|Walker | | | | |
+--------+---------------+--------+------------+-------------------------------+
The 1,863 shares purchased represent approximately 0.01 per cent. of the
Company's issued share capital.
The issued share capital of the Company comprises 15,538,518 ordinary shares.
This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 as amended by regulation 11 of the Market Abuse
(Amendment) (EU Exit) Regulations 2019/310.
For further enquiries, please contact:
4basebio PLC
Dr Amy Walker, CEO
+44 (0)12 2396 7943
Cairn Financial Advisers LLP (Nominated Adviser)
Jo Turner / Sandy Jamieson / Ed Downes
+44 (0)20 7213 0880
Cavendish Capital Markets Limited (Joint Broker)
Geoff Nash / Nigel Birks
+44 (0)20 7220 0500
RBC Capital Markets (Joint Broker)
Kathryn Deegan / Matthew Coakes
+44 (0)20 7653 4000
ICR Healthcare (Media and Investor Relations)
Mary-Jane Elliott / Jessica Hodgson
+44 (0)203 707 5700
About 4basebio
4basebio (AIM: 4BB) is a Cambridge-based biotechnology company pioneering the
use of synthetic DNA to enable next-generation therapeutics and vaccines.
Through its proprietary enzymatic DNA synthesis platform, 4basebio produces GMP
-grade synthetic DNA and mRNA with superior speed, purity, and scalability,
overcoming the limitations of plasmid-based systems. The company offers
application-specific DNA constructs tailored to the diverse needs of gene
therapies, genome editing, mRNA production, and DNA vaccines, helping partners
accelerate proof-of-concept studies and reach clinical milestones more
efficiently while maintaining the highest standards of safety and quality.
For more information, visit 4basebio.com (https://www.4basebio.com/).
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
+--+----------------+------------------------------+
|1 |Details of the |
| |persons |
| |discharging |
| |managerial |
| |responsibilities |
| |/ person closely |
| |associated |
+--+----------------+------------------------------+
|a)|Name |Dr. Amy Walker |
+--+----------------+------------------------------+
|2 |Reason for the |
| |notification |
+--+----------------+------------------------------+
|a)|Position/Status |Chief Executive Officer |
+--+----------------+------------------------------+
|b)|Initial |Initial notification |
| |notification/ | |
| |Amendment | |
+--+----------------+------------------------------+
|3 |Details of the |
| |issuer, emission |
| |allowance market |
| |participant, |
| |auction |
| |platform, |
| |auctioneer or |
| |auction monitor |
+--+----------------+------------------------------+
|a)|Name |4basebio plc |
+--+----------------+------------------------------+
|b)|LEI |213800E2DX9EAIUNCB30 |
+--+----------------+------------------------------+
|4 |Details of the |
| |transaction(s): |
| |section to be |
| |repeated for (i) |
| |each type of |
| |instrument; (ii) |
| |each type of |
| |transaction; |
| |(iii) each date; |
| |and (iv) each |
| |place where |
| |transactions |
| |have been |
| |conducted |
+--+----------------+------------------------------+
|a)|Description of |Ordinary Shares |
| |the financial | |
| | |ISIN: GB00BMCLYF79 |
| |instrument, type| |
| |of | |
| | | |
| |instrument | |
| | | |
| |Identification | |
| |code | |
+--+----------------+------------------------------+
|b)|Nature of the |Acquisition of ordinary shares|
| |transaction | |
+--+----------------+------------------------------+
|c)|Price(s) and |Price: 509.00p |
| |volume(s) | |
| | |Volume: 1,863 |
+--+----------------+------------------------------+
|d)|Aggregated |See above |
| |information | |
| | | |
| |-Aggregated | |
| |volume | |
| | | |
| |-Aggregated | |
| |Price | |
+--+----------------+------------------------------+
|e)|Date of |21 May 2026 |
| |transaction | |
+--+----------------+------------------------------+
|f)|Place of |London Stock Exchange |
| |transaction | |
+--+----------------+------------------------------+
This information was brought to you by Cision http://news.cision.com